News & Events

The Firm recently represented the underwriters, led by Goldman, Sachs & Co. and Citigroup Global Markets Inc., in connection with a registered follow-on public offering of 17,825,000 shares of common stock, including shares issued upon the full exercise of the underwriters’ over-allotment option, by Human Genome Sciences, Inc. (Nasdaq: HGSI), resulting in gross proceeds of approximately $476.8 million.

Human Genome Sciences, headquartered in Rockville, Maryland, is a commercially focused biopharmaceutical company with a clinical pipeline that includes three novel products in late-stage development: BENLYSTA^TM for systemic lupus erythematosus; ZALBIN^TM for chronic hepatitis C; and ABthrax^TM for inhalation anthrax. In November 2009, BENLYSTA^TM successfully met its primary endpoint in the second of two Phase 3 clinical trials in systemic lupus erythematosus. BENLYSTA^TM is the first medicine being developed specifically for lupus that has reached this late stage of clinical development with positive results.

The Simpson Thacher team included Michael Nathan, Mark Brod, Elsa Wang and Lulu Liu (Corporate); Noah Leibowitz and Alex Key (IP); and Andrew Pagliughi (Blue Sky). Paralegal Matthew Dresher provided valuable assistance.